SCHEMBL1848725

SCHEMBL1848725

CCNc1nccc(-c2cn(Cc3ccc(OC)cc3)nc2-c2cccc(N)c2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 2/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 1/20 0.50
CDK5R1 Q15078 1/20 0.50
MKNK1 Q9BUB5 1/20 0.46
DYRK1A Q13627 4/20 0.45
CLK4 Q9HAZ1 4/20 0.45
CLK1 P49759 3/20 0.45
DYRK1B Q9Y463 3/20 0.45
BRAF P15056 3/20 0.45
CLK2 P49760 2/20 0.45
ACVR1 Q04771 6/20 0.42
MAPK13 O15264 1/20 0.41
RAF1 P04049 1/20 0.41
MAPK9 P45984 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41
MAPK14 Q16539 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1846924 0.87 KMT2A (0.45) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL1847299 0.86 KMT2A (0.43) MEN1KMT2AMKNK1DYRK1ACLK4
SCHEMBL1849954 0.84 CDK5 (0.45) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL1849329 0.79 BRAF (0.44) DYRK1ACLK4DYRK1BBRAFACVR1
SCHEMBL1852300 0.79 MAPK8 (0.42) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL1854213 0.77 MAPK8 (0.47) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL1846559 0.77 MAPK8 (0.44) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL1974617 0.76 MAPK8 (0.46) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL1847064 0.75 MAPT (0.44) MEN1KMT2ACLK1
SCHEMBL1850886 0.72 ACHE (0.41) MEN1KMT2AACVR1MAPK9CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946250-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-02-03 US disclosed
CN-102105459-B 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES SRL 2014-09-10 CN disclosed
US-20140005150-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-01-02 US disclosed
US-8541575-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-24 US disclosed
EP-2324008-B1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2012-05-09 EP disclosed
CN-102105459-A 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES SRL 2011-06-22 CN disclosed
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-06-16 US disclosed
EP-2324008-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-25 EP disclosed
WO-2010010154-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005150-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K3, MAP3K19, MAP3K15 CDK5 95/4885MEN1 2780/4885NPC1 3775/4885
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K3, MAP3K19, MAP3K15 CDK5 95/4885MEN1 2780/4885NPC1 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.